PE20191144A1 - Inhibidores de magl - Google Patents
Inhibidores de maglInfo
- Publication number
- PE20191144A1 PE20191144A1 PE2019001014A PE2019001014A PE20191144A1 PE 20191144 A1 PE20191144 A1 PE 20191144A1 PE 2019001014 A PE2019001014 A PE 2019001014A PE 2019001014 A PE2019001014 A PE 2019001014A PE 20191144 A1 PE20191144 A1 PE 20191144A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hexafluoropropan
- trifluoromethyl
- cr6r7
- oxobutyl
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title 1
- 101710116393 Monoglyceride lipase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- -1 2 - ((4 - (((1,1,1,3,3,3-hexafluoropropan-2-yl) oxy) carbonyl) piperazin-1-yl) methyl) -5- (trifluoromethyl) phenoxy Chemical group 0.000 abstract 2
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 abstract 2
- 108020002334 Monoacylglycerol lipase Proteins 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 208000021722 neuropathic pain Diseases 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000002621 endocannabinoid Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423099P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191144A1 true PE20191144A1 (es) | 2019-09-02 |
Family
ID=62106678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001014A PE20191144A1 (es) | 2016-11-16 | 2017-11-15 | Inhibidores de magl |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10093635B2 (enExample) |
| EP (1) | EP3541821A4 (enExample) |
| JP (1) | JP7042547B2 (enExample) |
| KR (1) | KR20190077544A (enExample) |
| CN (1) | CN110267963B (enExample) |
| AR (1) | AR110089A1 (enExample) |
| AU (1) | AU2017361251B2 (enExample) |
| BR (1) | BR112019009994A2 (enExample) |
| CA (1) | CA3043615A1 (enExample) |
| CL (1) | CL2019001339A1 (enExample) |
| CO (1) | CO2019005059A2 (enExample) |
| CR (1) | CR20190241A (enExample) |
| DO (1) | DOP2019000122A (enExample) |
| EA (1) | EA038090B1 (enExample) |
| EC (1) | ECSP19035077A (enExample) |
| GE (2) | GEAP202215088A (enExample) |
| IL (1) | IL266523B (enExample) |
| JO (1) | JOP20190106A1 (enExample) |
| MA (1) | MA46857A (enExample) |
| MX (1) | MX391117B (enExample) |
| NI (1) | NI201900051A (enExample) |
| PE (1) | PE20191144A1 (enExample) |
| PH (1) | PH12019501097A1 (enExample) |
| RU (1) | RU2754536C1 (enExample) |
| TN (1) | TN2019000153A1 (enExample) |
| TW (1) | TWI756299B (enExample) |
| UA (1) | UA124542C2 (enExample) |
| WO (1) | WO2018093947A1 (enExample) |
| ZA (1) | ZA201903100B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| CN109996790B (zh) | 2016-09-19 | 2023-05-16 | H.隆德贝克有限公司 | 哌嗪氨基甲酸酯及其制备和使用方法 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2017361254B2 (en) | 2016-11-16 | 2021-09-23 | H. Lundbeck A/S. | Pharmaceutical formulations |
| PE20191239A1 (es) | 2016-11-16 | 2019-09-16 | Abide Therapeutics Inc | Formas cristalinas de un inhibidor de magl |
| DK3630744T3 (da) | 2017-05-23 | 2023-03-06 | H Lundbeck As | Pyrazol-magl-inhibitorer |
| UA126685C2 (uk) | 2017-08-29 | 2023-01-11 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Сполуки, які є модуляторами magl, і способи їх отримання і застосування |
| EP3793547A4 (en) | 2018-05-15 | 2021-11-17 | H. Lundbeck A/S | MAGL INHIBITORS |
| EP3914589A4 (en) * | 2019-01-25 | 2022-11-30 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
| WO2021097107A1 (en) * | 2019-11-15 | 2021-05-20 | Lundbeck La Jolla Research Center, Inc. | Crystalline forms of a magl inhibitor |
| IT202000007150A1 (it) * | 2020-04-03 | 2021-10-03 | Univ Pisa | Inibitori di monoacilglicerolo lipasi (magl) |
| AU2021259496A1 (en) | 2020-04-21 | 2022-11-10 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
| IL316302A (en) | 2022-05-04 | 2024-12-01 | H Lundbeck As | Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (enExample) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| DE69211015T2 (de) | 1991-11-27 | 1997-01-09 | Du Pont | Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate |
| AU1384795A (en) | 1993-12-22 | 1995-07-10 | Shell Internationale Research Maatschappij B.V. | Process for preparing carbamates |
| JP2000500448A (ja) | 1995-11-15 | 2000-01-18 | ゼネカ リミテッド | 除草性置換ピラゾール化合物 |
| AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| WO2001025188A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
| EP1716130A1 (en) | 2004-02-18 | 2006-11-02 | AstraZeneca AB | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| EP1831218A2 (en) | 2004-12-23 | 2007-09-12 | F.Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| EP1836179B1 (en) | 2004-12-30 | 2015-05-06 | Janssen Pharmaceutica NV | Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
| EP1948630A2 (en) * | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| CN101711154A (zh) | 2007-02-26 | 2010-05-19 | 科森生物科学公司 | 氨基甲酸酯化合物 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| US20110118286A1 (en) | 2008-07-16 | 2011-05-19 | Santhosh Francis Neelamkavil | Bicyclic heterocycle derivatives and their use as gpcr modulators |
| US8772318B2 (en) | 2008-11-14 | 2014-07-08 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| CA2755806A1 (en) | 2009-03-23 | 2010-09-30 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| AU2010239188B2 (en) * | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| RU2570662C9 (ru) | 2009-11-03 | 2016-07-20 | Байер Матириальсайенс Аг | Фторуретаны в качестве добавки в фотополимерной композиции |
| FR2960875B1 (fr) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| LT2800743T (lt) | 2012-01-06 | 2018-06-25 | Agios Pharmaceuticals, Inc. | Terapiškai aktyvūs junginiai ir jų panaudojimo būdai |
| MX350788B (es) * | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| US9567302B2 (en) | 2012-03-19 | 2017-02-14 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| JP2014005245A (ja) * | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| MX2015017961A (es) * | 2013-07-03 | 2016-10-14 | Abide Therapeutics Inc | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. |
| US10570146B2 (en) | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| CN109996790B (zh) * | 2016-09-19 | 2023-05-16 | H.隆德贝克有限公司 | 哌嗪氨基甲酸酯及其制备和使用方法 |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2017
- 2017-06-16 JO JOP/2019/0106A patent/JOP20190106A1/ar unknown
- 2017-11-15 MA MA046857A patent/MA46857A/fr unknown
- 2017-11-15 GE GEAP202215088A patent/GEAP202215088A/en unknown
- 2017-11-15 MX MX2019005776A patent/MX391117B/es unknown
- 2017-11-15 US US15/814,322 patent/US10093635B2/en active Active
- 2017-11-15 UA UAA201905620A patent/UA124542C2/uk unknown
- 2017-11-15 JP JP2019523587A patent/JP7042547B2/ja not_active Expired - Fee Related
- 2017-11-15 TN TNP/2019/000153A patent/TN2019000153A1/en unknown
- 2017-11-15 WO PCT/US2017/061868 patent/WO2018093947A1/en not_active Ceased
- 2017-11-15 IL IL266523A patent/IL266523B/en unknown
- 2017-11-15 EP EP17871753.4A patent/EP3541821A4/en not_active Withdrawn
- 2017-11-15 CN CN201780083663.6A patent/CN110267963B/zh not_active Expired - Fee Related
- 2017-11-15 KR KR1020197016924A patent/KR20190077544A/ko not_active Abandoned
- 2017-11-15 AU AU2017361251A patent/AU2017361251B2/en not_active Ceased
- 2017-11-15 PE PE2019001014A patent/PE20191144A1/es unknown
- 2017-11-15 RU RU2019116512A patent/RU2754536C1/ru active
- 2017-11-15 GE GEAP201715088A patent/GEP20237470B/en unknown
- 2017-11-15 EA EA201991073A patent/EA038090B1/ru unknown
- 2017-11-15 AR ARP170103184A patent/AR110089A1/es not_active Application Discontinuation
- 2017-11-15 CA CA3043615A patent/CA3043615A1/en active Pending
- 2017-11-15 BR BR112019009994A patent/BR112019009994A2/pt not_active IP Right Cessation
- 2017-11-15 CR CR20190241A patent/CR20190241A/es unknown
- 2017-11-16 TW TW106139775A patent/TWI756299B/zh not_active IP Right Cessation
-
2019
- 2019-05-16 DO DO2019000122A patent/DOP2019000122A/es unknown
- 2019-05-16 CL CL2019001339A patent/CL2019001339A1/es unknown
- 2019-05-16 PH PH12019501097A patent/PH12019501097A1/en unknown
- 2019-05-16 NI NI201900051A patent/NI201900051A/es unknown
- 2019-05-16 EC ECSENADI201935077A patent/ECSP19035077A/es unknown
- 2019-05-16 CO CONC2019/0005059A patent/CO2019005059A2/es unknown
- 2019-05-17 ZA ZA201903100A patent/ZA201903100B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191146A1 (es) | Inhibidores de magl | |
| PE20211655A1 (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| PE20211385A1 (es) | Inhibidores de magl | |
| PE20121280A1 (es) | Derivados de (tio)morfolina como moduladores de s1p | |
| PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
| PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
| PE20150021A1 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
| PE20161400A1 (es) | Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| PE20170444A1 (es) | Herbicidas de piperidinona | |
| AR072224A1 (es) | Derivados de pirimidona sustituidos | |
| UY36743A (es) | Nuevos 3-fenil-pirrolidin-2,4-diona alquinil-sustuidos y sus usos como herbicidas | |
| PE20091816A1 (es) | Inhibidores de bace | |
| PE20170326A1 (es) | Herbicidas de piridazinona | |
| AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
| CL2021001119A1 (es) | Composición de control de organismos nocivos y método para usar la misma | |
| PE20120937A1 (es) | Compuestos derivados de quinolina y quinoxalina como agentes antivirales | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| PE20080136A1 (es) | Arilsulfonamidas sustituidas como agentes antivirales | |
| MX2014015789A (es) | Composicion herbicida que tiene actividad herbicida mejorada. | |
| PE20060357A1 (es) | Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| MX2019007104A (es) | Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso. | |
| PE20181319A1 (es) | Compuestos de isoindol | |
| PE20170251A1 (es) | Novedosas pirimidinas 2,5-sustituidas |